Sionna Therapeutics (NASDAQ:SION) Downgraded to Hold Rating by Lifesci Capital

Sionna Therapeutics (NASDAQ:SION) was downgraded by investment analysts at Lifesci Capital from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other equities research analysts have also commented on SION. Royal Bank Of Canada upgraded shares of Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price target on the stock in a research note on Monday. Citizens Jmp lowered Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. JonesTrading cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 20th. Finally, Guggenheim downgraded Sionna Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $42.22.

Sionna Therapeutics Trading Up 13.3%

Shares of SION opened at $5.10 on Monday. The firm has a market capitalization of $230.58 million, a price-to-earnings ratio of -2.34 and a beta of 1.32. The firm’s fifty day simple moving average is $40.99 and its 200-day simple moving average is $39.92. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). On average, analysts predict that Sionna Therapeutics will post -2.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director owned 2,469,959 shares in the company, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is owned by company insiders.

Institutional Trading of Sionna Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG lifted its position in Sionna Therapeutics by 91.1% during the 4th quarter. UBS Group AG now owns 89,177 shares of the company’s stock worth $3,669,000 after acquiring an additional 42,511 shares during the period. Vanguard Group Inc. increased its holdings in shares of Sionna Therapeutics by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 1,184,951 shares of the company’s stock valued at $48,749,000 after purchasing an additional 41,797 shares during the period. Jennison Associates LLC raised its stake in shares of Sionna Therapeutics by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock worth $45,883,000 after purchasing an additional 117,903 shares during the last quarter. Candriam S.C.A. acquired a new stake in shares of Sionna Therapeutics during the first quarter worth $9,494,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Sionna Therapeutics during the fourth quarter worth $26,290,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Negative Sentiment: SION-719 failed its Phase 2 primary endpoint. The experimental cystic-fibrosis treatment did not produce the expected improvement, prompting Sionna to discontinue development of SION-719 as an add-on therapy. The failure eliminates the company’s principal near-term clinical catalyst and raises uncertainty about the value of its broader pipeline. Sionna Therapeutics Halts Lead Cystic Fibrosis Drug After Phase 2 Failure
• Negative Sentiment: The stock dropped roughly 90% to a record low. The magnitude of the decline reflects investors’ reassessment of Sionna’s prospects following the unexpected trial miss and the loss of its lead drug program. Trading volume was also unusually heavy compared with the company’s average. Sionna Therapeutics stock falls 92% after SION-719 trial failure
• Negative Sentiment: Analysts cut their ratings after the clinical setback. BTIG and Guggenheim moved from “buy” to “neutral,” while Raymond James, Citizens JMP and Wedbush also reduced their ratings. Wedbush and RBC set approximately $5 price targets, signaling limited expected upside at current levels. Sionna Discontinues Cystic Fibrosis Drug Following Unfavorable Data
• Neutral Sentiment: Sionna reported mixed results from two cystic-fibrosis programs and plans to refocus its pipeline. However, the company has not yet identified a replacement asset with comparable clinical maturity, leaving its future strategy and financing needs uncertain. Sionna Reports Mixed Trial Results and Refocuses CF Pipeline
• Neutral Sentiment: The failure benefits rival Vertex Pharmaceuticals. Sionna’s unsuccessful trial removes a potential competitor to Vertex’s established cystic-fibrosis franchise, which explains why Vertex shares rose as Sionna’s stock declined. Vertex Shares Rise as Rival Sionna Trial Fails

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.